- November 25th, 2021
- Category: press
Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON
The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology
Joint Press Release
Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON
The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology
Liege (BE), 25/11/2021 - Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical images with OncoDNA’s expertise in tumor characterization via testing both solid and liquid biopsies for relevant cancer biomarkers.
The two Belgian companies will work together within the scope of the SALMON (meaSure lung cAncer bioLogy and treatMent respOnse via imaging) clinical study. Radiomics’ prospective, multi-center, multi-country study is aimed at validating its AI approach in the oncology space. Biopsy samples and imaging data will be collected from subjects with non-small cell lung cancer (NSCLC) to chart a non-invasive radiomics atlas of oncogenic biomarkers based on imaging features of computed tomography scans ("rAtlas"). Furthermore, the workflow of assessment of therapy response will be automated by using artificial intelligence on follow up CT scans ("aRECIST").
Radiomics plans to start the recruitment stage from early 2022. “We welcome OncoDNA’s expertise for this important milestone in the use of imaging and AI. With this study we aim at the comprehension and characterization of non-small cell lung cancer, the most common type of lung cancer accounting for 84% of all lung cancer diagnoses.”said Wim Vos, CEO of Radiomics.
While Radiomics will lead the radiological characterization of the cases included in the SALMON study through its proprietary advanced technology based on the extraction of quantitative information from DICOM scans, OncoDNA will generate comprehensive OncoKDM reports for the biological characterization and genetic sequencing of NSCLC patients via tissue and liquid biopsy, aimed at the analysis of circulating tumor DNA in blood for the close surveillance of disease progression.
“We believe pairing Radiomics science with our technology platform will prove the value of combining technologies and result in a major step ahead for the development of new solutions for cancer treatment” said Bernard Courtieu, CEO of OncoDNA.
With great enthusiasm and eager to further explore the potential of their technologies, Radiomics looks forward to launching its SALMON clinical study and to start working with OncoDNA, bringing insights in support of pharma and clinical practice decision makers.
About Radiomics
Founded in 2016 and based in Liège, Radiomics (www.radiomics.bio) is a Belgian AI-powered research organization for next-generation image analysis, based on the unique experience of its founders, pioneers in radiomic science. Since its foundation, the company has diversified and greatly expanded its service offerings. Although oncology remains one of its priority areas, its objective is to develop radiomics applications in various therapeutic areas, thanks in particular to its potential in the respiratory field. Radiomics uses its advanced image analysis technology based on artificial intelligence (AI), deep learning and federated learning to uncover hidden information in standard medical images. Its goal is to support decision-making through insights and optimize pharmaceutical and biotech companies’ clinical trials and drug development studies and providing clinicians with a patient-centered approach based on personalized medicine. For further information, visit www.radiomics.bio and connect through Linkedin, Facebook or Twitter.
About OncoDNA
OncoDNA is a theranostic and genomic company with renown expertise in precision medicine. The company provieds comprehensive testing of cancer biomarkers (DNA, RNA and proteins) on solid and liquid biopsies as well NGS data interpretation services to oncologists, research institutes and biopharmaceutical companies across the globe. The company headquarters are based in Belgium, and its two entites – IntegraGen, a company specializing in the decryption of the human genome and Biosequence – are headquartered in France and Spain, respectively. The group employs approx. 115 employees in 9 countries, works with an international network of 35 distributors and collaborates with one European-based and one US-based subcontracted accredited laboratories. For further information, visit www.oncodna.com and connect through Linkedin, Facebook or Twitter.
Media contacts
Fabrizia Candido,
Account & PR Manager
[email protected]
Mélanie Moxhet,
External Communications & Digital Marketing Leader
[email protected]
![[:swvar:ufile:1:description:]](/swfiles/files/logo-radiomics.svg?nc=1709282693){kind=logo}